These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30798641)

  • 1. Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer.
    Ottestad L; Fronth L; Rajendiran S; Hege Aksnes L; Eikesdal HP; Støre Blix E; Ewertz M
    Acta Oncol; 2019 Mar; 58(3):385-387. PubMed ID: 30798641
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H; Stoetzer O; Decker T; Kurbacher CM; Marmé F; Schneeweiss A; Mundhenke C; Distelrath A; Fasching PA; Lux MP; Lüftner D; Hadji P; Janni W; Muth M; Kreuzeder J; Quiering C; Taran FA
    Int J Cancer; 2019 Feb; 144(4):877-885. PubMed ID: 29992557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
    Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
    Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR
    Bardia A; Modi S; Oliveira M; Cortes J; Campone M; Ma B; Dirix L; Weise A; Hewes B; Diaz-Padilla I; Han Y; Deshpande P; Samant TS; Lorenc KR; He W; Su F; Chavez-MacGregor M
    Clin Cancer Res; 2020 Dec; 26(24):6417-6428. PubMed ID: 32998962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
    Ciruelos E; Vidal M; Martínez de Dueñas E; Martínez-Jáñez N; Fernández Y; García-Sáenz JA; Murillo L; Carabantes F; Beliera A; Fonseca R; Gavilá J
    Clin Transl Oncol; 2018 Jun; 20(6):753-760. PubMed ID: 29116433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
    Pritchard KI; Burris HA; Ito Y; Rugo HS; Dakhil S; Hortobagyi GN; Campone M; Csöszi T; Baselga J; Puttawibul P; Piccart M; Heng D; Noguchi S; Srimuninnimit V; Bourgeois H; Gonzalez Martin A; Osborne K; Panneerselvam A; Taran T; Sahmoud T; Gnant M
    Clin Breast Cancer; 2013 Dec; 13(6):421-432.e8. PubMed ID: 24267730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
    O'Shaughnessy J; Thaddeus Beck J; Royce M
    Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial.
    Jerusalem G; de Boer RH; Hurvitz S; Yardley DA; Kovalenko E; Ejlertsen B; Blau S; Özgüroglu M; Landherr L; Ewertz M; Taran T; Fan J; Noel-Baron F; Louveau AL; Burris H
    JAMA Oncol; 2018 Oct; 4(10):1367-1374. PubMed ID: 29862411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
    Lüftner D; Schuetz F; Schneeweiss A; Hartkopf A; Bloch W; Decker T; Uleer C; Stötzer O; Foerster F; Schmidt M; Mundhenke C; Tesch H; Jackisch C; Fischer T; Kreuzeder J; Guderian G; Fasching PA
    Int J Cancer; 2024 Jul; 155(1):128-138. PubMed ID: 38447007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus Plus Letrozole for Treatment of Patients With HR
    Safra T; Kaufman B; Kadouri L; Efrat Ben-Baruch N; Ryvo L; Nisenbaum B; Evron E; Yerushalmi R
    Clin Breast Cancer; 2018 Apr; 18(2):e197-e203. PubMed ID: 29097108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
    Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
    Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
    Steger GG; Egle D; Bartsch R; Pfeiler G; Petru E; Greil R; Helfgott R; Marth C; Öhler L; Hubalek M; Lang A; Tinchon C; Haslbauer F; Redl A; Hock K; Hennebelle M; Mraz B; Gnant M
    Breast; 2020 Apr; 50():64-70. PubMed ID: 32062536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.
    Yardley DA; Noguchi S; Pritchard KI; Burris HA; Baselga J; Gnant M; Hortobagyi GN; Campone M; Pistilli B; Piccart M; Melichar B; Petrakova K; Arena FP; Erdkamp F; Harb WA; Feng W; Cahana A; Taran T; Lebwohl D; Rugo HS
    Adv Ther; 2013 Oct; 30(10):870-84. PubMed ID: 24158787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.
    Xie Y; Li Y; Zhang Y; Zhang S; Li W; Guan X; Zhao Y; Gong C; Hu X; Zhang J; Cao E; Wang L; Ge R; Wang B
    Clin Breast Cancer; 2019 Jun; 19(3):e452-e458. PubMed ID: 30846408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
    Bilici A; Uysal M; Menekse S; Akin S; Yildiz F; Turan M; Sezgin Goksu S; Beypinar I; Sakalar T; Değirmenci M; Erdem D; Basaran G; Olmez OF; Avci N; Tural D; Sakin A; Turker S; Demir A; Temiz S; Kaplan MA; Dogan M; Tanriverdi O; Bilgetekin I; Cinkir HY; Acikgoz O; Paydas S; Uslu R; Turhal S
    Cancer Invest; 2022 Feb; 40(2):199-209. PubMed ID: 34894960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations.
    Del Mastro L; Cazzaniga M; Solidoro P; Generali D; Bianchi G; Testore F; De Placido S
    Future Oncol; 2015; 11(16):2251-4. PubMed ID: 26260802
    [No Abstract]   [Full Text] [Related]  

  • 18. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
    de Glas NA; Fontein DB; Bastiaannet E; Pijpe A; De Craen AJ; Liefers GJ; Nortier HJ; de Haes HJ; van de Velde CJ; van Leeuwen FE
    Cancer; 2014 Sep; 120(18):2847-54. PubMed ID: 24840230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
    Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
    Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant sunitinib plus exemestane in post-menopausal women with hormone receptor-positive/HER2-negative early-stage breast cancer (SUT_EXE-08): a phase I/II trial.
    Fullana B; Morales S; Petit A; Alay A; Verdaguer H; Climent F; Navarro-Perez V; Cejuela M; Galvan P; Gumà A; Llombart-Cussac A; Cordero D; Casanovas O; Prat A; Gil-Gil M; Pernas S
    Sci Rep; 2024 Oct; 14(1):23626. PubMed ID: 39384801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.